Market Place
Sourcing Support
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
02 Dec 2024 //
GLOBENEWSWIRE
NKGen Biotech Receives Nasdaq Notifications on Delayed Report
26 Nov 2024 //
GLOBENEWSWIRE
NKGen Biotech Presents Troculeucel Data in Alzheimer’s at CTAD
29 Oct 2024 //
GLOBENEWSWIRE
NKGen Biotech Upcoming Presentation At World Stroke Congress 2024
15 Oct 2024 //
GLOBENEWSWIRE
NKGen Biotech Announces Presentations At CTAD Conference
08 Oct 2024 //
GLOBENEWSWIRE
NKGen Biotech Advances Troculeucel To Phase 2 For Alzheimer`s
12 Sep 2024 //
GLOBENEWSWIRE
NKGen Biotech to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Report
22 Aug 2024 //
GLOBENEWSWIRE
NKGen Biotech Presents SNK01 Biomarker Data At AAIC 2024
30 Jul 2024 //
GLOBENEWSWIRE
NKGen Biotech To Present SNK01 Alzheimer`s Trial Data At 2024 Conference
18 Jul 2024 //
GLOBENEWSWIRE
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
15 Jul 2024 //
GLOBENEWSWIRE
NKGen Biotech Presents Updated Phase 1 Data On SNK02 At Summit
12 Jun 2024 //
GLOBENEWSWIRE
NKGen To Present SNK02 Allo NK Cell Therapy Phase 1 Solid Tumor Data
03 Jun 2024 //
GLOBENEWSWIRE
Nkgen Snk02 Nk Phase 1: Advanced Solid Tumors At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
NKGen`s SNK01 NK Cleared For Alzheimer`s Phase 2 Trial
20 May 2024 //
GLOBENEWSWIRE
NKGen Biotech To Present On Autologous NK Cell Therapy
16 May 2024 //
GLOBENEWSWIRE
NKGen Biotech Gets FDA IND Clearance for SNK01 in Parkinson`s
29 Apr 2024 //
GLOBENEWSWIRE
NKGen Presents Updated NK Cell Therapy Data at Alzheimer`s Summit
25 Apr 2024 //
GLOBENEWSWIRE
NKGen Biotech to Present at ASCO 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
NKGen Biotech Presenting SNK01 NK Cell Therapy At Alzheimer`s Summit
18 Apr 2024 //
GLOBENEWSWIRE
NKGen Biotech Raises $5M To Advance Clinical Programs
11 Apr 2024 //
GLOBENEWSWIRE
NKGen Biotech Presents Additional Ph 1 Trial Data in ADisease at the Tau2024
25 Mar 2024 //
GLOBENEWSWIRE
NKGen Biotech Announces Upcoming Presentation on SNK01
04 Mar 2024 //
GLOBENEWSWIRE
NKGen Announces Dosing of First Patient in its Phase 1/2a Trial with SNK01
28 Dec 2023 //
GLOBENEWSWIRE
NKGen Biotech Announces Clearance of Trial Application by HC for SNK01
27 Dec 2023 //
GLOBENEWSWIRE
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
NKGen Presented Phase I Clinical Trial Data at the 16th Annual CTAD Conference
26 Oct 2023 //
GLOBENEWSWIRE
NKGen Biotech Announces FDA Clearance of Investigational NDA for SNK01
24 Oct 2023 //
GLOBENEWSWIRE
NKGen Biotech Announces Poster Presentation at CTAD Conference
19 Oct 2023 //
GLOBENEWSWIRE
NKGen Presents Interim Phase I Trial Data at the XXVI WCN Annual Meeting 2023
17 Oct 2023 //
GLOBENEWSWIRE
NKGen Announces Poster Presentation at the XXVI WCN Annual Meeting 2023
11 Oct 2023 //
GLOBENEWSWIRE
NKGen Biotech, Inc. Announces Closing of Business Combination
02 Oct 2023 //
GLOBENEWSWIRE
NKGen Bio to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
21 Sep 2023 //
GLOBENEWSWIRE
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting
30 Aug 2023 //
GLOBENEWSWIRE
NKGen Biotech Announces First Patient Dosed in Phase I Clinical Trial of SNK02
24 Aug 2023 //
GLOBENEWSWIRE
Graf Acquisition Corp. IV and NKGen Biotech Announce Effectiveness of Form S-4
15 Aug 2023 //
GLOBENEWSWIRE
NKGen and Graf Announce the Nomination of Directors for the Board of Directors
09 Aug 2023 //
GLOBENEWSWIRE
NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimers Conference
17 Jul 2023 //
GLOBENEWSWIRE
NKGen Announces Poster Presentation at the 2023 International Conference
10 Jul 2023 //
GLOBENEWSWIRE
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event
06 Jul 2023 //
GLOBENEWSWIRE
NKGen to Present at 2nd International Alzheimer`s Disease Conference 2023
13 Jun 2023 //
GLOBENEWSWIRE
NKGen Biotech Announces SNK01 Preclinical & Phase I/IIa Clinical Data Presented
05 Jun 2023 //
GLOBENEWSWIRE
NKGen Announces Poster Presentation at the 2023 ASCO Annual Meeting
25 May 2023 //
GLOBENEWSWIRE
NKGen Biotech to Present at the (ASGCT)
02 May 2023 //
GLOBENEWSWIRE
NKGen to Become Publicly Traded Company via Combination with Graf Acquisition
14 Apr 2023 //
GLOBENEWSWIRE
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
10 Jan 2023 //
GLOBENEWSWIRE
NKGen and Parkinson’s Foundation partner to advance cell therapy
07 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation
04 Nov 2022 //
GLOBENEWSWIRE
NKGen Biotech Receives IND Clearance from FDA for SNK02
17 Oct 2022 //
GLOBENEWSWIRE
NKGen Biotech Announces in Journal of Cancer Research and Cellular Therapeutics
21 Sep 2022 //
GLOBENEWSWIRE
NKGen Biotech to Present at the Baird 2022 Global Healthcare Conference
07 Sep 2022 //
GLOBENEWSWIRE
NKGen Biotech To Present SNK01 Clinical Data at the (ESMO) Congress 2022
06 Sep 2022 //
GLOBENEWSWIRE
NKGen Biotech to Participate in Truist Securities Cell Therapy Symposium
21 Jun 2022 //
GLOBENEWSWIRE
NKGen Biotech To Present SNK01 Clinical Data at the 2022 ASCO Annual Meeting
26 May 2022 //
GLOBENEWSWIRE
